Specialty Pharmacy Times: May/June 2016

From the Chairman
Editorial
Patient Satisfaction: The Real Barometer for Success in Specialty
Misinformation among consumers and the media regarding specialty pharmacies illustrates the importance of leveraging factual information to highlight specialty services for patients to raise the customer service bar even higher.
Viewpoints: The Last Word
Three Current Policy Discussions Influencing Cancer Drug Development
Despite progress in reducing cancer mortality, more work is needed to improve patient outcomes in this disease state.
In Practice
Not Just a Generic: Specialty Pharmacy Considerations for a Biosimilar Launch
As new biosimilars enter the market, pharmacies should carefully consider infrastructure, resources, and strategies for successfully integrating the products into their portfolio of offerings.
Features
Adherence to Oral Oncolytics Requires a Clinically Integrated Approach to Specialty Pharmacy
Despite initiatives that help patients maintain adherence, health care providers still need to leverage their collective resources and work together to overcome this tremendous hurdle in cancer care.
Specialty Drug Copay Coupons: Despite Patient Benefits, Compliance Issues Persist
Conflicting opinions surround drug copay coupons, which can improve out-of-pocket costs while decreasing the effectiveness of cost-sharing requirements that promote prudent prescribing and purchasing choices.
Challenges Continue for True Patient-Centered Access
Access to oral chemotherapies is filled with challenges for providers and patients that can be significant, resulting in delayed therapy.
Cancer: The Next Frontier in Chronic Care Management
As with care for any chronic condition, the goals for advanced oncology therapies should be improving outcomes, containing costs, and increasing medication adherence.
Understanding Closed-System Transfer Devices: Why They Are Important and How to Select an Appropriate System
CSTDs can help protect health care workers, including pharmacists and nurses, from hazardous chemotherapy drugs.
Powering Decision Support for Specialty Drugs: How Technology is Keeping Pace with Therapeutic Breakthroughs in Hepatitis C and Oncology
Physicians are challenged with differentiating among a wide array of treatment options, with varying regimens and indications, and then monitoring patients according to the specific guidelines for each therapy.
New Drug Review
Granix by Teva Pharmaceuticals, Inc
Granix is a human granulocyte factor produced in a bioreactor using recombinant DNA technology.
Disease State Management
CE Highlights

Most Popular

Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$